SARAH ABIGAIL MARDIKIAN PA-C
Prescription History 1609508340
Physician Assistant in Missoula, MT

NPI Status: Active since June 30, 2022

Contact Information

1211 SW HIGGINS AVE APT D
MISSOULA, MT
ZIP 59803
Phone: (406) 880-3486

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SARAH ABIGAIL MARDIKIAN PA-C, an active Physician Assistant specialist practicing in Missoula, MT. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 61 documented patient claims. Among these therapy options, the most frequently utilized medication is Cephalexin, which accounts for 27 claims alone.

Medication Index

No matching medications currently found on file.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 58
MT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply311
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside MT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $94.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.89

State Avg Cost Per Claim

$9.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Cephalexin

Generic Formulation: CephalexinSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 168
MT State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.6
Peer Average Days Supply322
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $235.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.74

State Avg Cost Per Claim

$7.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Paxlovid (Eua)

Generic Formulation: Nirmatrelvir/RitonavirSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 55
MT State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.1
Peer Average Days Supply96
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside MT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.55

State Avg Cost Per Claim

$10.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Triamcinolone Acetonide

Generic Formulation: Triamcinolone AcetonideSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 113
MT State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply854
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.6% less volume than the regional standard for practitioners inside MT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $90.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.25

State Avg Cost Per Claim

$9.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.

Therapeutic Applications

This medication is used in a variety of conditions such as allergic disorders, arthritis, gout, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders, collagen and skin diseases. Talk to your doctor about the risks and benefits of triamcinolone, especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use. Triamcinolone is known as a corticosteroid hormone (glucocorticoid). It works by decreasing your body's immune response to these diseases and reduces symptoms such as swelling.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SARAH ABIGAIL MARDIKIAN PA-C provides transparency into local medical care patterns within Missoula, MT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.